Experienced multidisciplinary management and advisory team

Board of Directors

The Board has an experienced multidisciplinary management and advisory team with a strong, proven record of developing and successful product commercialisation.

Executive Board Members

Otto Buttula

Otto Buttula

Executive Chairman

Mr Buttula has had extensive experience and success in investment research, funds management and information technology and has held directorships in a number of public companies. Mr Buttula’s executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. The company grew from a market capitalisation of $48 million at listing before a takeover in 2007 by Commonwealth Bank of Australia for $373 million.

Read More

Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited.

Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit & Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.

Trevor Lockett

Trevor Lockett PhD

Technical Director

Trevor trained as a molecular biologist at the University of Adelaide and the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that has become ColoSTAT®.

Read More

He has extensive experience in intellectual property creation and management and is an inventor on nine patent families, all of which have either been licensed or are in commercialisation. He is an author of over 100 scientific publications.

Non-Executive Board Members

Sue MacLeman

Sue MacLeman

Independent, Deputy Chair

Sue has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at ScheringPlough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector.

Read More

Sue is a Non-Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also a member of the NSW Innovation and Productivity Council, Fellow of the Australian Academy of Technology and Engineering (ATSE) and Fellow/Graduate of Australian Institute of Company Directors (AICD). Sue is also appointed to several academic and government advisory boards.

Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School.


Dr Rachel David

Non Executive Director

Rachel is an experienced senior health and financial services sector executive with a deep understanding of the complex interplay between government, business, media and the community which underpin the economic challenges and opportunities faced by Australia’s health care system. Rachel’s career has spanned over 25 years during which she has delivered significant value by promoting policy change to address the significant economic problems and market failures in healthcare, particularly relating to evidence-based practice and access to new technologies.

Read More

Rachel holds a Bachelor of Medicine, Bachelor of Surgery (MBBS), Master of Business Administration (MBA) and is a graduate of the Australian Institute of Company Directors. Rachel is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA), the peak organisation representing Australia’s 23 major health funds, which represent 98% of the industry. This includes the two major listed companies, Medibank and nib. Primarily a policy and advocacy organisation, PHA works with Australian Governments on ensuring policy and regulatory settings are enabling sustainability and growth in the private health sector. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.

Lou Panaccio

Lou Panaccio

Non-Executive Director

A chartered accountant with extensive management experience in business and healthcare services. He is currently on the boards of ASX listed companies Sonic Healthcare Limited, Adherium Limited, Magellan Stem Cells Pty Ltd. and Avita Medical Limited. Lou is also on the board of NeuralDX Limited and Unison Housing Limited.

Read More

Lou has more than twenty years’ experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.

About us:



Rhythm Biosciences

Bio21 Institute
30 Flemington Road
Parkville VIC 3010

Keep up to date:

Please provide your full name
You must provide an email address

Connect with us: